Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Geron Corp GERNW


Primary Symbol: GERN

Healthcare Biotechnology
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GERN)

Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights

Business Wire 2 days ago

Geron to Announce First Quarter 2024 Financial Results on May 2, 2024

Business Wire 8 days ago

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 18, 2024

Geron to Participate at Upcoming Investor Conferences in April

Business Wire April 3, 2024

Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Business Wire March 19, 2024

Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

Business Wire March 14, 2024

Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Business Wire February 28, 2024

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire February 22, 2024

Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

Business Wire February 14, 2024
View More News ››

Opinion & Analysis (NDAQ:GERN)

Drug pricing, presidential politics, and three biotechs with promise

The Life Sciences Report April 13, 2016

Stock picks including a coal play

J.W. Cotton November 4, 2009

Profiting from the 'picks and shovels' of stem cell research

Andrew Mickey January 27, 2009

Make money from the next emerging boom

Andrew Mickey November 25, 2008

Cash-rich companies for the bear-market bounce

Jason Schwarz November 7, 2008
View More Opinion ››

Bullboard Posts (NDAQ:GERN)

Jim Cramer: This Tech Stock Is 'Great,' Archer Aviation Is '

News; $GERN Jim Cramer: This Tech Stock Is 'Great,' Archer Aviation Is 'Too Speculative For Me' | BenzingaOn CNBC@s @Mad...
whytestocks - April 11, 2024

BUY BUY BUY BUY BUY

Tnews is good
Nibinator - March 14, 2024

BUY BUY BUY BUY BUY

Tnews is good
Nibinator - March 14, 2024

GERON CORPORATION: A LOT IS RIDING ON IMETELSTAT!

$GERN Geron Corporation (NASDAQ: GERN) is a late-stage clinical biotechnology company developing a first-in-class telomerase inhibitor,...
AviseAnalytics - June 17, 2022

still holding this stock

my target of $3 per share should be easily reached in the quarter,so glta shareholders.
coolfooldumbguy - February 13, 2019

this was way oversold

people always seem to over react with panic,so glta.
coolfooldumbguy - October 5, 2018
View more Bullboard ››

Vertex Resource Group Ltd.

Vertex Resource Group Ltd.

Vertex Resource Group Ltd. is a Canada-based provider of environmental and industrial services. It provides environmental ...
View More »